DIAMEDICA THERAPEUTICS INC. (DMAC)
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
📈 **POSITIVE** • Medium confidence analysis (75%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business